Clinical Trial Update: Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Completed Phase 1 multicenter dose-escalation study evaluating the combination of pazopanib and bevacizumab in patients with metastatic renal cell carcinoma and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Solid Tumors

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Metastatic Renal Cell Carcinoma, Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed | Phase 1 | Status: COMPLETED